VANCOUVER, May 17 /PRNewswire/ — Xenon
Pharmaceuticals Inc. is pleased to announce today that it has
appointed Tarek S. Mansour as
Executive Vice President, Research and Development.
“We are delighted to welcome Tarek to the Xenon team,” commented
Simon Pimstone, Xenon’s President
and CEO. “Tarek is a world-class R&D executive whose experience
in discovering products, a number of which are now on the market,
will further enhance Xenon’s capabilities. Tarek has had the
unique experience of holding senior leadership positions within
both biotech and more traditional pharmaceutical companies.
His successful careers at Biochem Pharma and Wyeth
Pharmaceuticals (now Pfizer) have armed Tarek with best-in-class
drug discovery and development practice and we are confident that
Tarek will make a major contribution to Xenon’s future innovative
R&D efforts.”
Dr. Mansour has spent nearly 25 years in the life sciences
industry with positions at Biochem Pharma, and Wyeth
Pharmaceuticals (now Pfizer). His most recent position at Wyeth
Research was as VP, Chemical Sciences Head over multiple research
sites. Dr. Mansour received his PhD in Chemistry from the University of Missouri – Columbia.
About Xenon Pharmaceuticals Inc.
Xenon is a privately owned, clinical genetics-based drug
discovery and development company engaged in developing small
molecule therapies focusing in the areas of pain, cardiometabolic
disease, and diseases of iron metabolism. Xenon has multiple
products in phase 1 and 2 clinical development. For more
information, visit the Company’s website at
